Enliven Therapeutics (ELVN) Jefferies Global Healthcare Conference 2025 summary

Company overview and lead program

• Clinical-stage precision oncology company focused on kinase drug discovery, with lead asset ELVN-001 targeting BCR-ABL in chronic myeloid leukemia (CML).

• Lead program aims to be a best-in-class ATP-competitive inhibitor in a revived CML market.

Recent and upcoming clinical data

• Phase I study in late-line CML patients showed a cumulative major molecular response (MMR) rate of 44% and a response achieved rate of 26%, consistent with precedent pivotal studies.

• Data update at EHA on June 13 will include more patients (low 50s efficacy evaluable, nearly 90 total), with some on study for over two years.

• The cutoff for the upcoming data presentation is end of April.

• Higher doses and optimal exposure cohorts are expected to yield better efficacy, with a growing proportion of patients at optimal dose levels.

Efficacy and dose optimization

• Achieved response rate has increased from 23.1% to 26% as more patients receive optimal dosing.

• Efficacy metrics are robust even in heavily pretreated populations, aligning with or exceeding benchmarks from drugs like asciminib and ponatinib.

• 80 mg selected as the first expansion dose based on PK, target coverage, and early clinical activity; higher doses show no additional efficacy benefit.